A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85% coverage when immunised four weeks before birth
- Maternal antibodies passed through the placenta safeguard newborns from day one
- Coverage possible with 2-week gap before early delivery
- Vaccination in third trimester still offers significant infant protection
Compelling evidence from recent research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a extensive research programme undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that half-year window, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s conclusions have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across varied populations and settings.
The results reveal a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This stark contrast highlights the vaccine’s vital importance in preventing serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospital admissions. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology measured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine works when given across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe properly. Parents frequently observe their babies visibly struggling, their chests heaving as they attempt to draw adequate oxygen into their weakened respiratory system. Whilst most infants recover with palliative treatment, a limited though important group succumb from RSV-related complications annually, making prevention through vaccination a essential public health objective for safeguarding the most vulnerable and youngest individuals in the population.
- RSV triggers inflammation in lungs, leading to serious respiratory problems in infants
- Half of all infants acquire the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies succumb to RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have stressed the significance of pregnant women receiving their jab at the best time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery delivers approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies via the placenta.
The messaging from public health bodies remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.
Regional differences in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and community involvement initiatives, though the national data demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to engage with women during pregnancy
- Inconsistencies across regions in vaccination coverage levels across England demand focused enhancement
- Community health services adapting programmes to suit community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness delivers concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this preventative solution, the 80% reduction in admissions represents thousands of infants protected against critical disease. Parents no longer face the troubling prospect of seeing their babies gasping for air or struggle to eat, symptoms that define serious RSV disease. The vaccine has substantially transformed the landscape of neonatal breathing health, providing expectant mothers a active means to safeguard their youngest infants during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused severe brain damage, the vaccine’s availability carries deep personal significance. His mother’s advocacy for the jab emphasises the transformative consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women in their third trimester, changing what was once an predictable seasonal threat into a manageable risk.